Alyftrek (vanzacaftor–tezacaftor–deutivacaftor), made by Vertex, represents the latest advance in CFTR modulator treatments that are transforming cystic fibrosis care by targeting the underlying cause ...

Research on γ-secretase reveals its unique substrate recognition mechanism, offering potential for developing precise ...

Aggression is a complex behavior dependent on numerous factors such as personal experiences, upbringing, social context, personality and genetics. Florian Reichmann and his team at the Med Uni Graz ...

Using artificial intelligence, researchers show how γ-secretase recognizes substrates – an important advance for fundamental ...

Scientists identified the mechanism by which a sea cucumber molecule inhibits sulfatase-2, an enzyme that’s often upregulated ...

Researchers have discovered a highly conserved post translational modification in the STING pathway that when inhibited stops ...

A group of researchers at the VIB‑UGent Center for Medical Biotechnology has developed a new platform to isolate and analyze ...

Center for Drug Evaluation (CDE) has granted approval to the investigational new drug (IND) application of InnoCare Pharma to ...

BEIJING, China I July 03, 2025 I InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

Hi! Recently, I have made some attempts to model transmembrane proteins with AlphaFold3 in the server, successfully adding up to 200 oleic acid molecules. Due to the purpose of my current research, ...